NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $1.38 -0.02 (-1.43%) (As of 09:52 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akebia Therapeutics alerts: Email Address About Akebia Therapeutics Stock (NASDAQ:AKBA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$1.37▼$1.4350-Day Range$0.98▼$1.5552-Week Range$0.78▼$2.48Volume141,168 shsAverage Volume3.40 million shsMarket Capitalization$289.24 millionP/E RatioN/ADividend YieldN/APrice Target$5.75Consensus RatingBuy Company OverviewAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More… My big AI project… (Ad)On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. Akebia Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 72nd PercentileAkebia Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 296th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.19) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -6.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Akebia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.10% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 0.63%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.35 Percentage of Shares Shorted9.10% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 0.63%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.24 News SentimentAkebia Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesHC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)September 8, 2024 | americanbankingnews.comBuy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo’s Market LaunchSeptember 7, 2024 | markets.businessinsider.com My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 17, 2024 | Brownstone Research (Ad)Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on DialysisSeptember 5, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | prnewswire.comAkebia Therapeutics to Present at Upcoming Investor ConferencesAugust 26, 2024 | prnewswire.comZacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and AkebiaAugust 19, 2024 | finance.yahoo.comOcuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.24 on January 1st, 2024. Since then, AKBA stock has increased by 12.9% and is now trading at $1.40. View the best growth stocks for 2024 here. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The biopharmaceutical company had revenue of $43.65 million for the quarter, compared to the consensus estimate of $45.61 million. Who are Akebia Therapeutics' major shareholders? Top institutional shareholders of Akebia Therapeutics include Alerce Investment Management L.P. (2.74%), Acadian Asset Management LLC (1.94%), Renaissance Technologies LLC (1.87%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/08/2024Today9/17/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year FoundedN/APrice Target and Rating Average Stock Price Target$5.75 High Stock Price Target$7.50 Low Stock Price Target$4.00 Potential Upside/Downside+316.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-23.18% Pretax Margin-23.18% Return on EquityN/A Return on Assets-17.54% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio0.82 Sales & Book Value Annual Sales$174.50 million Price / Sales1.66 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-8.63Miscellaneous Outstanding Shares209,596,000Free Float201,003,000Market Cap$289.24 million OptionableOptionable Beta0.77 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:AKBA) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows th...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
